Navigation Links
Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
Date:10/27/2009

NASHVILLE, Tenn., Oct. 27 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it will report third quarter 2009 financial results before the market opens on Tuesday, November 10, 2009. A conference call and live Internet webcast will be held on Tuesday, November 10, 2009 at 10:00 a.m. Eastern Time to discuss the results.

To participate on the call, please dial 888-417-8462 (for U.S. callers) or 719-457-2552 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 888-203-1112 (for U.S. callers) or 719-457-0820 (for international callers). The passcode for the rebroadcast is 9695498. The live webcast and rebroadcast can be accessed via Cumberland Pharmaceuticals' website at http://investor.shareholder.com/cpix/events.cfm.

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote® for the treatment of acetaminophen poisoning and Kristalose®, a prescription laxative. The Company also recently launched Caldolor®, the first injectable treatment for pain and fever available in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed its initial public offering of common stock in August 2009.

For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.

SOURCE: Cumberland Pharmaceuticals Inc.

SOURCE Cumberland Pharmaceuticals Inc.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/15/2017)... 2017 Enterin Inc., a Philadelphia ... (PD), today announced the completion of a $12.7 million Series ... III, as well as the participation of existing investors. ... have the support of New Ventures III and our current ... of the potential of our platform technology to transform the ...
(Date:7/13/2017)... Calif. , July 13, 2017 RK Logistics ... Board of Pharmacy certification for its Fremont, CA ... support solutions in the Tri-Valley and San Jose ... City of Fremont , with its Fremont ... Group to provide such a powerful resource to the hundreds ...
(Date:7/11/2017)... July 11, 2017 Zymo Research Corp., also known as ,The ... quantify biological aging in a precise manner using the myDNAge ™ ... , a professor of human genetics and biostatistics at the David ... Public Health , Zymo Research,s proprietary DNAge ™ technology is used ... ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The ... offer patients improved quality of life five years after injury, according to research ... Meeting in Toronto, Ontario, Canada. The study followed patients for five years following ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a leading provider ... JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. McCarter, formerly ... Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, brings 30 ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... law firm headquartered in Houston, is pleased to announce their expansion to the ... affordable housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John ...
(Date:7/20/2017)... ... ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission of education, ... with a Microsoft Corp. employee-led hackathon team for the 2017 Microsoft One Week Hackathon ... 1’s mission overlaps seamlessly with Microsoft’s mission to empower every person and every organization ...
(Date:7/20/2017)... ... 2017 , ... Girl Up Campaign Director, Melissa Kilby, released ... support of providing girls access to education in refugee settings. In May, Congressman Steve ... Access to Education in Vulnerable Settings Act.” Yesterday, companion legislation was introduced in ...
Breaking Medicine News(10 mins):